BioCryst Pharmaceuticals
BCRX
165 hedge funds and large institutions have $635M invested in BioCryst Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 55 increasing their positions, 37 reducing their positions, and 21 closing their positions.
238% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $3.31M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
159% more capital invested
Capital invested by funds: $245M → $635M (+$390M)
148% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 21
49% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 37
23% more funds holding
Funds holding: 134 → 165 (+31)
4.01% less ownership
Funds ownership: 79.51% → 75.5% (-4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$39.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$11.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$9.49M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.43M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$7.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15M |
| 3 |
EP
Eversept Partners
New York
|
-$10.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$9.76M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.83M |
BCRX Hedge Fund Activity: Q2 2020 in Review
165 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2020, worth a combined $635M — up 159% from $245M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new BCRX positions and 21 closed out — a net gain of 31 holders — while 55 added to existing stakes and 37 trimmed.
The largest buyer was State Street, adding an estimated $39.3M. The largest seller was UBS Group, cutting an estimated $19.7M.
- 165 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2020, up from 134 in Q1 2020.
- Funds reported $635M of BioCryst Pharmaceuticals stock for Q2 2020, up 159% quarter-over-quarter.
- 52 funds opened new BioCryst Pharmaceuticals positions in Q2 2020 and 21 closed out, a net change of +31 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2020 was State Street, an estimated $39.3M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2020 was UBS Group, an estimated $19.7M sold.
Based on aggregated 13F filings for Q2 2020.